Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.0770 |
| Open | 0.0920 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0770 - 0.0920 |
| 52 Week Range | 0.0102 - 0.3999 |
| Volume | 1,811 |
| Avg. Volume | 21,488 |
| Market Cap | 291,585 |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0580 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- GlobeNewswire
Lexington Biosciences Announces Appointment of CEO
Lexington Biosciences, Inc. (CSE:LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by the resignation of Eric Willis. Since 1993, Mr. McInnes has been the founder, president and a director of a number of public natural resource companies.
© 2021 Verizon Media. All rights reserved.
